Oslo, Norway 19, February 2025
Oncoinvent AS, a clinical stage company advancing alpha emitter therapy across a
variety of solid cancers, today announced that members of management will be
presenting the company and participate in the following conferences:
-February 28th - B. Riley Securities Precision Oncology & Radiopharma Conference
-March 3-5th - TD Cowen Health Care Conference, Boston
-March 11-12th - Carnegie Healthcare Seminar, Stockholm
-March 17-19th - BIO Europe Spring, Milan
About Oncoinvent
Oncoinvent is a clinical-stage biotechnology company developing novel
radiopharmaceutical therapies against cancer. The lead product candidate,
Radspherin, uses the alpha-emitting radionuclide radium-224, directly targeting
micro-metastases post-surgery, harnessing the benefits of modern
radiopharmaceuticals without the complexities of biological targeting.
Oncoinvent is investigating the safety and efficacy of Radspherin in a clinical
development program in two indications. Currently two phase 1/2a trials and one
randomized phase 2 trial are ongoing in the US, UK and Europe. More than 150
patients with peritoneal carcinomatosis, secondary to ovarian and colorectal
cancer, will be enrolled in the current program. Preliminary clinical efficacy
data are highly encouraging, and no serious toxicity or safety concerns have
been reported to date. The Oncoinvent team consists of approx. 30 employees and
runs a state-of-the-art manufacturing facility to produce drug products for
clinical trials in Nydalen, Oslo. Oncoinvent is listed on the Euronext Growth
Oslo.
Forward-Looking Statements
All statements other than statements of historical facts contained in this press
release are forward-looking statements and are not a representation that
Oncoinvent's plans, estimates, or expectations will be achieved. These
forward-looking statements represent Oncoinvent's expectations as of the date of
this press release, and Oncoinvent disclaims any obligation to update the
forward-looking statements. These forward-looking statements are subject to
known and unknown risks and uncertainties that may cause actual results to
differ materially, including with respect to whether the results of clinical or
other studies will support the use of our product offerings, the impact of
results of such studies, our expectations of the reliability, accuracy and
performance of our tests, or of the benefits of our tests and product offerings
to patients, providers and payers.
For further information, please contact:
Øystein Soug, Chief Executive Officer
Email: soug@oncoinvent.com
Tore Kvam, Chief Financial Officer
Email: kvam@oncoinvent.com